The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Current trials in colorectal cancer investigating panitumumab
Surgery is commonly the first line of treatment for colorectal cancer patients; however, alternative treatment options are currently being investigated in clinical trials. Here, Hani Babiker, MD, of the University of Arizona Cancer Center, Tucson, AZ, discusses the results from three recent clinical trials, highlighting a role for panitumumab/FOLFOX (leucovorin, 5-fluorouracil and oxaliplatin) combination therapy in patients with KRAS and NRAS mutations. Dr Babiker, speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, also discusses results from the VALENTINES trial, also investigating panitumumab combination therapy, before analyzing outcomes from the ASPECCT trial (NCT01001377).
